263 related articles for article (PubMed ID: 15948033)
1. Pharmacokinetics and modeling of quercetin and metabolites.
Chen X; Yin OQ; Zuo Z; Chow MS
Pharm Res; 2005 Jun; 22(6):892-901. PubMed ID: 15948033
[TBL] [Abstract][Full Text] [Related]
2. Absorption and enterohepatic circulation of baicalin in rats.
Xing J; Chen X; Zhong D
Life Sci; 2005 Nov; 78(2):140-6. PubMed ID: 16107266
[TBL] [Abstract][Full Text] [Related]
3. Co-administration of quercetin and catechin in rats alters their absorption but not their metabolism.
Silberberg M; Morand C; Manach C; Scalbert A; Remesy C
Life Sci; 2005 Nov; 77(25):3156-67. PubMed ID: 15979103
[TBL] [Abstract][Full Text] [Related]
4. Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model.
Marier JF; Vachon P; Gritsas A; Zhang J; Moreau JP; Ducharme MP
J Pharmacol Exp Ther; 2002 Jul; 302(1):369-73. PubMed ID: 12065739
[TBL] [Abstract][Full Text] [Related]
5. Quercetin pharmacokinetics in humans.
Moon YJ; Wang L; DiCenzo R; Morris ME
Biopharm Drug Dispos; 2008 May; 29(4):205-17. PubMed ID: 18241083
[TBL] [Abstract][Full Text] [Related]
6. A physiologically based kinetic (PBK) model describing plasma concentrations of quercetin and its metabolites in rats.
Boonpawa R; Spenkelink A; Rietjens IM; Punt A
Biochem Pharmacol; 2014 May; 89(2):287-99. PubMed ID: 24561179
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic comparison between quercetin and quercetin 3-O-β-glucuronide in rats by UHPLC-MS/MS.
Yang LL; Xiao N; Li XW; Fan Y; Alolga RN; Sun XY; Wang SL; Li P; Qi LW
Sci Rep; 2016 Oct; 6():35460. PubMed ID: 27775094
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, protein binding and metabolic profile of 3H-icometasone enbutate following intravenous, oral and intratracheal administrations to Sprague-Dawley rats.
Duchêne P; Giudicelli MD; Neau B; Gronfier A; Firmin Y; Villax P; Saivin S; Houin G
Arzneimittelforschung; 1998 Apr; 48(4):371-8. PubMed ID: 9608879
[TBL] [Abstract][Full Text] [Related]
9. The disposition and pharmacokinetics of ketoconazole in the rat.
Remmel RP; Amoh K; Abdel-Monem MM
Drug Metab Dispos; 1987; 15(6):735-9. PubMed ID: 2893696
[TBL] [Abstract][Full Text] [Related]
10. Conjugated metabolites represent the major circulating forms of Abelmoschus manihot in vivo and show an altered pharmacokinetic profile in renal pathology.
Guo J; Du L; Shang E; Li T; Liu Y; Qian D; Tang Y; Duan J
Pharm Biol; 2016; 54(4):595-603. PubMed ID: 26186460
[TBL] [Abstract][Full Text] [Related]
11. First-pass metabolism and biliary recirculation of droloxifene in the female Sprague-Dawley rat.
Nickerson DF; Tess DA; Toler SM
Xenobiotica; 1997 Mar; 27(3):257-64. PubMed ID: 9141233
[TBL] [Abstract][Full Text] [Related]
12. Analysis in the rat of 4-hydroxynonenal metabolites excreted in bile: evidence of enterohepatic circulation of these byproducts of lipid peroxidation.
Laurent A; Alary J; Debrauwer L; Cravedi JP
Chem Res Toxicol; 1999 Oct; 12(10):887-94. PubMed ID: 10525263
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and metabolism of the new thromboxane A2 receptor antagonist ramatroban in animals. 1st communication: absorption, concentrations in plasma, metabolism, and excretion after single administration to rats and dogs.
Boberg M; Ahr HJ; Beckermann B; Bühner K; Siefert HM; Steinke W; Wünsche C; Hirayama M
Arzneimittelforschung; 1997 Aug; 47(8):928-38. PubMed ID: 9296279
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and bioavailability of the isoflavone biochanin A in rats.
Moon YJ; Sagawa K; Frederick K; Zhang S; Morris ME
AAPS J; 2006 Jul; 8(3):E433-42. PubMed ID: 17025260
[TBL] [Abstract][Full Text] [Related]
15. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.
Yamaguchi T; Nakajima Y; Mizobuchi M; Inazawa K; Kanazu T; Kadono K; Ohkawa T; Iwatani K
Arzneimittelforschung; 1998 Oct; 48(10):995-1006. PubMed ID: 9825117
[TBL] [Abstract][Full Text] [Related]
16. The metabolic and pharmacokinetic disposition of mebendazole in the rat.
Allan RJ; Watson TR
Eur J Drug Metab Pharmacokinet; 1983; 8(4):373-81. PubMed ID: 6673974
[TBL] [Abstract][Full Text] [Related]
17. Heteroconjugates of quercetin with 4'-
Tanaka S; Trakooncharoenvit A; Nishikawa M; Ikushiro S; Hara H
Food Funct; 2022 Feb; 13(3):1459-1471. PubMed ID: 35048937
[TBL] [Abstract][Full Text] [Related]
18. Use of physiologically based kinetic (PBK) modeling to study interindividual human variation and species differences in plasma concentrations of quercetin and its metabolites.
Boonpawa R; Moradi N; Spenkelink A; Rietjens IM; Punt A
Biochem Pharmacol; 2015 Dec; 98(4):690-702. PubMed ID: 26441251
[TBL] [Abstract][Full Text] [Related]
19. Gender-related pharmacokinetics and absolute bioavailability of diosbulbin B in rats determined by ultra-performance liquid chromatography-tandem mass spectrometry.
Yang B; Wang X; Liu W; Zhang Q; Chen K; Ma Y; Wang C; Wang Z
J Ethnopharmacol; 2013 Oct; 149(3):810-5. PubMed ID: 23954278
[TBL] [Abstract][Full Text] [Related]
20. Intestinal disposition of quercetin and its phase-II metabolites after oral administration in healthy volunteers.
Chalet C; Rubbens J; Tack J; Duchateau GS; Augustijns P
J Pharm Pharmacol; 2018 Aug; 70(8):1002-1008. PubMed ID: 29761870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
